

Andreu Fernández-Codina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1408385/publications.pdf>

Version: 2024-02-01

158
papers

9,208
citations

117625

34
h-index

43889

91
g-index

162
all docs

162
docs citations

162
times ranked

9840
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
3	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016, 387, 2630-2640.	13.7	505
4	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 32-38.	0.9	394
5	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.7	321
6	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 212-220.	0.9	236
7	Treatment Algorithms for Systemic Sclerosis According to Experts. <i>Arthritis and Rheumatology</i> , 2018, 70, 1820-1828.	5.6	185
8	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
9	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
10	Campylobacter Reactive Arthritis: A Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 37, 48-55.	3.4	156
11	Current and future status of JAK inhibitors. <i>Lancet, The</i> , 2021, 398, 803-816.	13.7	117
12	The Minimally Important Difference for the Health Assessment Questionnaire in Rheumatoid Arthritis Clinical Practice Is Smaller Than in Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2009, 36, 254-259.	2.0	115
13	IgG4-Related Disease. <i>Medicine (United States)</i> , 2015, 94, e1275.	1.0	98
14	C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 219-229.	3.4	95
15	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 50-74.	1.2	87
16	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 648-656.	0.9	79
17	Prognosis of Seronegative Patients in a Large Prospective Cohort of Patients with Early Inflammatory Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2361-2369.	2.0	71
18	Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. <i>Rheumatology</i> , 2017, 56, 1144-1153.	1.9	71

#	ARTICLE	IF	CITATIONS
19	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.9	71
20	Raynaud's phenomenon—an update on diagnosis, classification and management. <i>Clinical Rheumatology</i> , 2019, 38, 3317-3330.	2.2	67
21	Scleroderma overlap syndromes. <i>Current Opinion in Rheumatology</i> , 2002, 14, 704-710.	4.3	63
22	Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2021, 48, 25-34.	2.0	60
23	Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. <i>Rheumatology International</i> , 2017, 37, 75-84.	3.0	58
24	The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1003-1008.	0.9	56
25	Musculoskeletal involvement in scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2003, 29, 391-408.	1.9	53
26	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	5.0	52
27	IgG4-related disease: Evidence from six recent cohorts. <i>Autoimmunity Reviews</i> , 2017, 16, 168-172.	5.8	48
28	Other Manifestations of Mixed Connective Tissue Disease. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 519-533.	1.9	46
29	The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2144-2151.	0.9	45
30	Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 331-337.	3.4	44
31	Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. <i>Immunotherapy</i> , 2019, 11, 737-754.	2.0	43
32	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1242-1248.	0.9	39
33	Monitoring of Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2018, 45, 1462-1476.	2.0	38
34	“Pregnancy in adult-onset idiopathic inflammatory myopathy”. Report from a cohort of myositis patients from a single center. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 234-240.	3.4	36
35	Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. <i>Journal of Clinical Medicine</i> , 2019, 8, 1394.	2.4	35
36	What Does the COVID-19 Pandemic Mean for Rheumatology Patients?. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 71-74.	1.4	35

#	ARTICLE	IF	CITATIONS
37	Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. <i>Journal of Rheumatology</i> , 2002, 29, 255-60.	2.0	35
38	The Frequency of Scleroderma Renal Crisis over Time: A Metaanalysis. <i>Journal of Rheumatology</i> , 2016, 43, 1350-1355.	2.0	34
39	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	3.9	34
40	New Classification Criteria for Systemic Sclerosis (Scleroderma). <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 383-398.	1.9	32
41	Opportunistic infections in patients with idiopathic inflammatory myopathies. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 487-496.	1.9	31
42	Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 467-474.	2.0	31
43	Are subjects satisfied with the informed consent process? A survey of research participants. <i>Journal of Rheumatology</i> , 2003, 30, 815-24.	2.0	31
44	Close association of herpes zoster reactivation and systemic lupus erythematosus (SLE) diagnosis: case-control study of patients with SLE or noninflammatory musculoskeletal disorders. <i>Journal of Rheumatology</i> , 2004, 31, 274-9.	2.0	30
45	Cardiac tamponade and severe pericardial effusion in systemic sclerosis: report of nine patients and review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1582-1592.	1.9	29
46	The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis. <i>Journal of Rheumatology</i> , 2004, 31, 140-9.	2.0	29
47	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 42-49.	1.7	25
48	Scleroderma treatment differs between experts and general rheumatologists. <i>Arthritis and Rheumatism</i> , 2006, 55, 138-145.	6.7	24
49	Does Socioeconomic Status Affect Outcomes in Early Inflammatory Arthritis? Data from a Canadian Multisite Suspected Rheumatoid Arthritis Inception Cohort. <i>Journal of Rheumatology</i> , 2015, 42, 46-54.	2.0	23
50	Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index. <i>Joint Bone Spine</i> , 2018, 85, 721-726.	1.6	23
51	Diagnosis and Management of Systemic Sclerosis: A Practical Approach. <i>Drugs</i> , 2016, 76, 203-213.	10.9	22
52	The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 685-690.	1.6	22
53	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019, 46, 751-754.	2.0	22
54	Carotid Artery Atherosclerosis in Patients with Active Rheumatoid Arthritis: Predictors of Plaque Occurrence and Progression Over 24 Weeks. <i>Open Rheumatology Journal</i> , 2016, 10, 49-59.	0.2	21

#	ARTICLE	IF	CITATIONS
55	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 813-817.	1.9	21
56	Scleroderma epidemiology update. <i>Current Opinion in Rheumatology</i> , 2021, 33, 122-127.	4.3	21
57	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021, 60, 1410-1418.	1.9	20
58	Emerging therapy options for IgG4-related disease. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 471-483.	3.0	20
59	Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. <i>Pancreatology</i> , 2021, 21, 1395-1401.	1.1	20
60	Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). <i>Autoimmunity Reviews</i> , 2020, 19, 102602.	5.8	19
61	Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021, 48, 852-858.	2.0	19
62	Anti-androgen treatment of prostatic carcinoma may be a risk factor for development of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002, 29, 2459-62.	2.0	19
63	Measuring the Rheumatology Workforce in Canada: A Literature Review. <i>Journal of Rheumatology</i> , 2016, 43, 1121-1129.	2.0	18
64	Lung transplantation in systemic sclerosis: A single center cohort study. <i>Joint Bone Spine</i> , 2018, 85, 79-84.	1.6	18
65	Meta-analysis of Treatment for Primary Sjögren's Syndrome. <i>Arthritis Care and Research</i> , 2020, 72, 1011-1021.	3.4	17
66	ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI). <i>RMD Open</i> , 2018, 4, e000738.	3.8	16
67	Repeat Testing of Antibodies and Complements in Systemic Lupus Erythematosus: When Is It Enough?. <i>Journal of Rheumatology</i> , 2018, 45, 827-834.	2.0	15
68	A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. <i>Rheumatology</i> , 2019, 58, 1393-1399.	1.9	15
69	Idiopathic retroperitoneal fibrosis: a clinicopathological study in 24 Spanish cases. <i>Clinical Rheumatology</i> , 2013, 32, 889-893.	2.2	14
70	Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1715-1724.	1.9	14
71	Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma?. <i>Autoimmunity Reviews</i> , 2020, 19, 102659.	5.8	14
72	Prevalence of osteoporosis in osteoarthritis: a systematic review and meta-analysis. <i>Osteoporosis International</i> , 2022, 33, 1687-1693.	3.1	14

#	ARTICLE	IF	CITATIONS
73	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. <i>Rheumatology</i> , 2016, 56, kew441.	1.9	13
74	Mixed Connective Tissue Disease and Epitope Spreading. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 155-159.	0.9	13
75	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 152-157.	1.9	13
76	Evolving patterns of reactive arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 2083-2088.	2.2	13
77	Response to Treatment in IgG4-Related Disease Assessed by Quantitative PET/CT Scan. <i>Clinical Nuclear Medicine</i> , 2021, 46, e307-e311.	1.3	13
78	Systemic sclerosis: To subset or not to subset, that is the question. <i>European Journal of Rheumatology</i> , 2020, 7, 222-227.	0.6	13
79	Incidence and prevalence of giant cell arteritis in Ontario, Canada. <i>Rheumatology</i> , 2020, 59, 3250-3258.	1.9	12
80	Systemic Sclerosis Classification: A Rose by Any Other Name Would Smell As Sweet?. <i>Journal of Rheumatology</i> , 2015, 42, 11-13.	2.0	11
81	Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort. <i>Rheumatology</i> , 2017, 56, 1111-1122.	1.9	11
82	Physician global assessments for disease activity in rheumatoid arthritis are all over the map!. <i>RMD Open</i> , 2018, 4, e000578.	3.8	11
83	Encounters with Rheumatologists in a Publicly Funded Canadian Healthcare System: A Population-based Study. <i>Journal of Rheumatology</i> , 2020, 47, 468-476.	2.0	11
84	Evaluation of Rheumatology Workforce Supply Changes in Ontario, Canada, from 2000 to 2030. <i>Healthcare Policy</i> , 2021, 16, 119-135.	0.6	11
85	Healthcare utilization and economic burden in systemic sclerosis: a systematic review. <i>Rheumatology</i> , 2022, 61, 3123-3131.	1.9	11
86	Severe myositis of the hip flexors after pre-operative chemoradiation therapy for locally advanced rectal cancer: case report. <i>BMC Cancer</i> , 2016, 16, 243.	2.6	10
87	Mentoring women in medicine: a personal perspective. <i>Lancet, The</i> , 2018, 391, 520-521.	13.7	10
88	The future of treatment in systemic sclerosis: can we design better trials?. <i>Lancet Rheumatology, The</i> , 2020, 2, e185-e194.	3.9	10
89	Performance of the 2019 ACR/EULAR classification criteria for IgG4-related disease and clinical phenotypes in a Spanish multicentre registry (REERIGG4). <i>Rheumatology</i> , 2021, 60, 217-223.	1.9	10
90	Feminization of the Rheumatology Workforce: A Longitudinal Evaluation of Patient Volumes, Practice Sizes, and Physician Remuneration. <i>Journal of Rheumatology</i> , 2021, 48, 1090-1097.	2.0	10

#	ARTICLE	IF	CITATIONS
91	The Temporal Relationship of Raynaud's Phenomenon and Features of Connective Tissue Disease in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 2329-2333.	2.0	9
92	Management of Raynaud's phenomenon in systemic sclerosis—a practical approach. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 102-110.	1.7	9
93	Radiography-based triage for COVID-19 in the Emergency Department in a Spanish cohort of patients. <i>Medicina Clínica</i> , 2022, 158, 466-471.	0.6	9
94	Stress in patients diagnosed with rheumatoid arthritis compared to chronic pain.. <i>Rehabilitation Psychology</i> , 2017, 62, 571-579.	1.3	9
95	The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 499-505.	3.4	8
96	Etiopatogenia, diagnóstico y tratamiento de la enfermedad relacionada con la IgG4. <i>Medicina Clínica</i> , 2018, 151, 18-25.	0.6	8
97	Utility of the ¹⁸ F-Florbetapir positron emission tomography in systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 109-114.	3.0	8
98	The relationship between NSAID use and osteoarthritis (OA) severity in patients with hip and knee OA: results of a case control study of NSAID use comparing those requiring hip and knee replacements to those in whom surgery was not recommended. <i>Medical Science Monitor</i> , 2008, 14, CR604-10.	1.1	8
99	The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 364.	1.9	7
100	Alteration of IgG4 levels in cerebrospinal fluid in IgG4-related disease. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1865-1867.	1.9	7
101	Update in ethiopathogeny, diagnosis and treatment of the IgG4 related disease. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 18-25.	0.2	7
102	Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2020, 39, 963-965.	2.2	7
103	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201594.	2.0	6
104	Ocular manifestations of Behçet's disease in children and adults: a systematic review and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 94-101.	0.8	6
105	Atypical scleromyxedema with prominent nodular lesions associated with immune thrombocytopenia: An unusual presentation. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e158-e159.	1.2	5
106	Idiopathic retroperitoneal fibrosis: IgG4 infiltration in a cohort of Spanish patients. <i>Rheumatology International</i> , 2014, 34, 1263-1265.	3.0	5
107	Dispositional Affect in Unique Subgroups of Patients with Rheumatoid Arthritis. <i>Pain Research and Management</i> , 2016, 2016, 1-9.	1.8	5
108	Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 149-152.	0.3	5

#	ARTICLE	IF	CITATIONS
109	Is It Time to Banish Composite Measures for Remission in Rheumatoid Arthritis?. Arthritis Care and Research, 2019, 71, 1300-1303.	3.4	5
110	How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology. Immunotherapy, 2020, 12, 1115-1119.	2.0	5
111	Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor. Open Rheumatology Journal, 2014, 8, 73-76.	0.2	5
112	Arthritis Clinical Trials at a Crossroad. Journal of Rheumatology, 2015, 42, 14-17.	2.0	4
113	Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity. Annals of Hepatology, 2019, 18, 215-219.	1.5	4
114	Giant Calcinosis in Dermatomyositis and Scleroderma Overlap. Arthritis and Rheumatology, 2020, 72, 1236-1236.	5.6	4
115	Immunosuppression use in early systemic sclerosis may be increasing over time. Journal of Scleroderma and Related Disorders, 2022, 7, 33-41.	1.7	4
116	Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years. Journal of Rheumatology, 2021, 48, 1427-1434.	2.0	4
117	Infections Are Not Increased in Scleroderma Compared to Non-Inflammatory Musculoskeletal Disorders Prior to Disease Onset. Open Rheumatology Journal, 2007, 1, 12-17.	0.2	4
118	Measuring the Impact of <scp>MyLupusGuide</scp> in Canada: Results of a Randomized Controlled Study. Arthritis Care and Research, 2023, 75, 529-539.	3.4	4
119	Clinical features and outcomes of COVID-19 in patients with IgG4-related disease: a European multi-centre study. Rheumatology, 2022, 61, e109-e111.	1.9	4
120	Tratamiento exitoso de un caso de pericarditis crónica constrictiva utilizando micofenolato sódico en una paciente con esclerosis sistémica. Medicina Clínica, 2017, 148, 574-575.	0.6	3
121	Pulmonary arterial hypertension in scleroderma: care gaps in screening. Arthritis Research and Therapy, 2017, 19, 128.	3.5	3
122	Therapeutic Options in IgG4-Related Disease. Current Treatment Options in Rheumatology, 2020, 6, 191-204.	1.4	3
123	Increased mortality for individuals with Giant Cell Arteritis: a population-based study. Arthritis Care and Research, 2021, , .	3.4	3
124	Appropriate cardiovascular disease risk assessment in systemic lupus erythematosus may be lacking in rheumatology practice. Clinical and Experimental Rheumatology, 2018, 36, 526-532.	0.8	3
125	A 40-Year-Old Woman With Back Pain. Chest, 2016, 150, e159-e165.	0.8	2
126	Enfermedad relacionada con la IgG4. Medicine, 2017, 12, 1716-1724.	0.0	2

#	ARTICLE	IF	CITATIONS
127	Trial methodology in scleroderma: Avoiding a shot in the dark. Rheumatology, 2017, 56, v1-v3.	1.9	2
128	What is the best treatment for early rheumatoid arthritis?. Rheumatology, 2019, 58, 2086-2088.	1.9	2
129	A comparison of rheumatoid arthritis and systemic lupus erythematosus trial design: a commentary on ways to improve the number of positive trials in SLE. Clinical and Experimental Rheumatology, 2015, 33, 671-80.	0.8	2
130	Guidelines on prescribing and monitoring antimalarials in rheumatic diseases: a systematic review. Clinical and Experimental Rheumatology, 2021, 39, 407-412.	0.8	2
131	A randomized, single-blinded cross-over trial of ischemic preconditioning in Raynaud's phenomenon. Journal of Scleroderma and Related Disorders, 2017, 2, 213-220.	1.7	1
132	OP0170â€¦USE OF THE PROVISIONAL EULAR/ACR IGG4-RD CLASSIFICATION CRITERIA IN A COHORT OF SPANISH PATIENTS. , 2019, , .		1
133	A cluster of non-tuberculosis mycobacterial infections in patients with connective tissue diseases. Medicina Clínica, 2020, 154, 468-469.	0.6	1
134	A cluster of non-tuberculosis mycobacterial infections in patients with connective tissue diseases. Medicina Clínica (English Edition), 2020, 154, 468-469.	0.2	1
135	Recommendations for the Treatment of Systemic Sclerosis: Agreement May Not Translate into Uptake. Journal of Rheumatology, 2020, 47, 164-165.	2.0	1
136	Osteoporosis and osteonecrosis in systemic lupus erythematosus. Revista Colombiana De Reumatología, 2021, 28, 3-11.	0.1	1
137	Health Care Utilization Is Increased In Systemic Sclerosis Patients Who Have Digital Ulcers. Arthritis Care and Research, 2022, , .	3.4	1
138	Sarcoidosis with complications. Internal and Emergency Medicine, 2014, 9, 817-818.	2.0	0
139	Successful treatment of constrictive chronic pericarditis with mycophenolate sodium in a patient with systemic sclerosis. Medicina Clínica (English Edition), 2017, 148, 574-575.	0.2	0
140	Takayasu's arteritis relapse. Joint Bone Spine, 2018, 85, 119.	1.6	0
141	R�cidive d�t�me art�rite de Takayasu. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 204.	0.0	0
142	IgG4-Related Disease, A Single-Center Experience. Journal of Clinical Rheumatology, 2021, 27, S590-S591.	0.9	0
143	Variations sous traitement du score d�t�activ�� de la maladie associ��e aux IgG4 (IgG4-RI). Revue Du Rhumatisme (Edition Francaise), 2019, 86, 373-379.	0.0	0
144	THU0588â€¦CLINICAL PHENOTYPES OF IGG4-RELATED DISEASE IN SPAIN. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
145	Immunoglobulin G ₄ -related disease as a mimicker of granulomatosis with polyangiitis: a case report. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 163-164.	1.1	0
146	Comment on: Incidence and prevalence of giant cell arteritis in Ontario, Canada: reply. <i>Rheumatology</i> , 2020, 59, e123-e124.	1.9	0
147	Fréquence de l'uvéïte chez les patients présentant une arthrite chronique juvénile. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020, 87, 247-252.	0.0	0
148	European consensus statements for interstitial lung disease in systemic sclerosis. <i>Lancet Rheumatology</i> , The, 2020, 2, e318-e319.	3.9	0
149	Fréquence de l'uvéïte chez les patients présentant une arthrite chronique juvénile. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020, , .	0.0	0
150	Arthritis in Systemic Sclerosis. In <i>Clinical Practice</i> , 2021, , 339-362.	0.0	0
151	1501â€¦Genetics of age at systemic lupus erythematosus diagnosis. , 2021, , .		0
152	Guidelines on prescribing and monitoring antimalarials in rheumatic diseases: a systematic review. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 407-412.	0.8	0
153	The erratic C-reactive protein: a novel outcome measure for longitudinal disease activity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
154	Ocular manifestations of Behçet's disease in children and adults: a systematic review and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 132, 94-101.	0.8	0
155	The erratic C-reactive protein: a novel outcome measure for longitudinal disease activity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	0
156	IgG4-Related Disease, A Single-Center Experience. <i>Journal of Clinical Rheumatology</i> , 2018, 27, 1.	0.9	0
157	To choose or not? The value of discrete-choice experiments in rheumatology. <i>Nature Reviews Rheumatology</i> , 0, , .	8.0	0
158	Radiography-based triage for COVID-19 in the Emergency Department in a Spanish cohort of patients. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 466-471.	0.2	0